H.C. Wainwright Comments On Neostem Following AMR-001 Data Release
In a research report published Wednesday, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Neostem (NASDAQ:NBS) with a $20 price target, as the company announced data from its 161 patient Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial.
Fein wrote, “We invite investors to consider the alternate scenario where the study had won its primary endpoint (surrogate marker) but shown no benefit in clinical outcome. In our view, the current scenario is friendlier to pivotal considerations.”
The analyst continued, “Going forward, we believe that further guidance on the path of AMR-001 will serve as an indicator of the asset’s (and this study’s) perceived value on business development tables (pending partnership or not). Ahead of such a de facto catalyst, following the stock’s sell-off that may have underestimated the importance of positive outcome data, and with the fundamentals of the commercial opportunity unchanged, we like the risk/reward of a long position.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Andrew Fein has a total average return of 6.2% and a 32.5% success rate. Fein has a average return when recommending NBS, and is ranked #1083 out of 3377 analysts.